Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sebi exempts trust...

    Sebi exempts trust linked to Alembic, Alembic Pharma from open offer requirement

    Written by Ruby Khatun Khatun Published On 2018-04-09T11:00:08+05:30  |  Updated On 9 April 2018 11:00 AM IST
    Sebi exempts trust linked to Alembic, Alembic Pharma from open offer requirement




    New Delhi: Markets regulator Sebi has exempted a private family trust related to the promoter group of Alembic Pharmaceuticals and Alembic from making open offers following proposed share transfers.

    Laksh Trust, through separate applications, had sought exemption from the obligation of making open offers post-acquisition of a certain number of shares in Alembic Pharma and Alembic.

    Chirayu Amin and Malika Amin are trustees of Laksh Trust.

    Malika Amin, one of the promoters, holds 1.59 percent and 2.25 percent stake directly in Alembic Pharma and Alembic respectively.

    She also holds shares in these four companies -- Nirayu Pvt Ltd, Whitefield Chemtech Pvt Ltd, Sierra Investments Pvt Ltd and Sherno Ltd. These four firms are promoter group entities of Alembic Pharma and Alembic.

    Under the proposal, the trust will acquire shares in the four promoter holding companies from Malika Amin.

    Post completion of the proposed acquisition, the trust would become part of the promoter entities in both the companies.

    Granting exemption, Sebi, in two separate orders, said the proposed acquisition is part of internal re-alignment of holdings within the promoter group family and there would be no change in control of both the companies following the proposed acquisition.

    "The proposed acquisition is further to an internal reorganization within the promoter family and is intended to streamline succession and promote the welfare of promoter family," Sebi said in similar-worded orders dated April 6.

    While providing the exemption with certain conditions, the watchdog also said the proposed acquisition should in accordance with the relevant provisions of the Companies Act and other applicable laws.

    Subsequently, the trust is required to file a report with Sebi within 21 days.

    Under takeover regulations, acquisition of shares beyond a certain threshold triggers the open offer obligation.



    AcquisitionAlembicAlembic PharmaAlembic PharmaceuticalsChemtech Pvt LtdChirayu AminexemptsLaksh TrustMalika AminNirayu Pvt Ltdopen offer requirementSEBIshare transferstrust
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok